

Vaccine Clinic Resource for Immunizers

Title:	COVID-19 Vaccine Moderna SPIKEVAX™ Quick Reference Guide
Formulation	mRNA vaccine, monovalent (XBB.1.5 Variant)
Effective Date:	September 22, 2023
Approver:	Final

Disclaimer: this Quick Reference is not intended to replace other product specific vaccine references. The document is intended as a quick reference for frequently referred to information. Please refer to the product monograph and other Moderna SPIKEVAX™ specific resources for all current and complete information.

COVID-19 Vaccine Resources:

Product Monographs: [Province of Manitoba | Resources for Health Care Providers- product monographs \(gov.mb.ca\)](#)

Storage and Handling: [storage-handling-chart.pdf \(gov.mb.ca\)](#)

Eligibility Criteria

For the most up to date information on COVID-19 vaccine dose eligibility criteria refer to [Province of Manitoba | Eligibility Criteria \(gov.mb.ca\)](#)

Canadian Immunization Guide:

For additional guidance on special populations: [COVID-19 vaccine: Canadian Immunization Guide- Vaccination of Specific Populations - Canada.ca](#)

For information on allergies/contraindications/precautions: [COVID-19 vaccine: Canadian Immunization Guide -Contraindications and Precautions - Canada.ca](#)

Fact Sheets:

For information on vaccine risk and intended benefits, refer to the [Province of Manitoba | Resources for the Public COVID-19 Fact Sheets \(gov.mb.ca\)](#)

MONOVALENT Moderna SPIKEVAX™ XBB.1.5 Variant Formulation: 6 months of age and older

Presentation & Recommendations	Storage & Handling	Administration (Dosage/ Schedule/ Route)					Potential Allergens																									
<p>Royal Blue cap Coral Blue label</p> <p>Supplied: 2.5 ml multidose vial Concentration: 0.10 mg/ml</p> <p>Number of doses per vial: 10 doses of 0.25ml per vial OR 5 doses of 0.5ml per vial</p> <p>Inspect vials: White/off-white dispersion and may contain white or translucent product-related particulates.</p> <p>If solution contains foreign particulates or discoloration, do not administer.</p>	<p>Thaw time: <u>2° to 8°C (Refrigerator):</u> ➤ 2 hours <i>After thawing, let vial stand at room temperature for 15 minutes before administering.</i> <u>15° to 25° C (Room temperature):</u> ➤ 45 min</p> <p>Storage: ➤ Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 30 days prior to first use. ➤ Unpunctured vials may be stored between 8° to 25°C (46° to 77°F) for up to 24 hours.</p> <p>Discard time: 24 hours at room or refrigerated temperature after first puncture. Do not refreeze.</p> <p>Handling: Swirl the vial gently after thawing and between each withdrawal. <u>Do not shake.</u></p> <p>Does NOT require dilution.</p>	<table border="1"> <thead> <tr> <th data-bbox="1303 373 1478 527">Age Range</th> <th data-bbox="1478 373 1653 527">COVID-19 Vaccination History</th> <th data-bbox="1653 373 1814 527">Dose Timing</th> <th data-bbox="1814 373 1975 527">Dose</th> <th data-bbox="1975 373 2136 527">Dose Volume</th> </tr> </thead> <tbody> <tr> <td data-bbox="1303 527 1478 657">6 months-4 years</td> <td data-bbox="1478 527 1653 657">Not previously vaccinated</td> <td data-bbox="1653 527 1814 657">2-dose series at least 4 weeks apart</td> <td data-bbox="1814 527 1975 657">2x25mcg</td> <td data-bbox="1975 527 2136 657">0.25ml</td> </tr> <tr> <td data-bbox="1303 657 1478 820"></td> <td data-bbox="1478 657 1653 820">Previously vaccinated (1 or more previous doses)</td> <td data-bbox="1653 657 1814 820">At least 6m after previous COVID-19 vaccine dose</td> <td data-bbox="1814 657 1975 820">25mcg</td> <td data-bbox="1975 657 2136 820"></td> </tr> <tr> <td data-bbox="1303 820 1478 917">5-11 years</td> <td data-bbox="1478 820 1653 917">Not previously vaccinated</td> <td data-bbox="1653 820 1814 917"></td> <td data-bbox="1814 820 1975 917">25mcg</td> <td data-bbox="1975 820 2136 917">0.25ml</td> </tr> <tr> <td data-bbox="1303 917 1478 1015">12 years and older</td> <td data-bbox="1478 917 1653 1015">OR previously vaccinated</td> <td data-bbox="1653 917 1814 1015"></td> <td data-bbox="1814 917 1975 1015">50mcg</td> <td data-bbox="1975 917 2136 1015">0.5ml</td> </tr> </tbody> </table> <p>Route: Intramuscular (IM) ➤ 6m to less than 12m of age: IM Anterolateral thigh ➤ 12m and older: IM Deltoid</p> <p>Recommended needle gauge and length: 22-25G 1"-1 ½" <i>Clinical judgement should be used when selecting needle length for IM injections. Consider client's weight, age and muscle mass.</i></p>					Age Range	COVID-19 Vaccination History	Dose Timing	Dose	Dose Volume	6 months-4 years	Not previously vaccinated	2-dose series at least 4 weeks apart	2x25mcg	0.25ml		Previously vaccinated (1 or more previous doses)	At least 6m after previous COVID-19 vaccine dose	25mcg		5-11 years	Not previously vaccinated		25mcg	0.25ml	12 years and older	OR previously vaccinated		50mcg	0.5ml	<p>Product is latex and preservative free</p> <p>Potential allergens:</p> <ul style="list-style-type: none"> • Polyethylene glycol (PEG), • Tromethamine (trometamol or Tris) <p><i>Individuals who have a known allergy to Tromethamine (trometamol or Tris), should not be immunized with COVID-19 vaccines containing Tromethamine (trometamol or Tris).</i></p> <p><i>Individuals who report an allergy to contrast material (CT dye), including gadolinium, can be immunized with vaccines containing Tromethamine (trometamol or Tris). They should be observed for 30 minutes post immunization.</i></p>
Age Range	COVID-19 Vaccination History	Dose Timing	Dose	Dose Volume																												
6 months-4 years	Not previously vaccinated	2-dose series at least 4 weeks apart	2x25mcg	0.25ml																												
	Previously vaccinated (1 or more previous doses)	At least 6m after previous COVID-19 vaccine dose	25mcg																													
5-11 years	Not previously vaccinated		25mcg	0.25ml																												
12 years and older	OR previously vaccinated		50mcg	0.5ml																												

Note: Individuals who started their primary series with the original monovalent or bivalent vaccines can complete their primary series with the updated XBB.1.5 formulation. Regardless of which product was used to start a primary series, the previous dose(s) should be counted and the series need not be restarted.

Additional Dose Recommendations: Moderately to Severely Immunocompromised^{1,2} (COVID-19 mRNA vaccines are the preferentially recommended COVID-19 vaccines)

If not previously immunized or if partially immunized against COVID-19:

Cohort	Product	Dose	Recommended Interval
6 months to 4 years	Moderna/ Spikevax™ XBB.1.5 (0.25 mL – 25 mcg) Blue cap/ Coral Blue label <i>(Preferential vaccine for this age group due to the shorter 3 dose regimen)</i>	3 dose series	4 to 8 weeks between doses <i>Your health care provider may recommend a different immunization schedule for you based on a review of your medical history and individual circumstances. A prescription is required for the additional doses.</i>
	Pfizer/Comirnaty™ XBB.1.5 (0.2mL – 3 mcg) Maroon cap/ Maroon label <i>Children who have received a dose of Pfizer/Comirnaty™ XBB.1.5 should receive Pfizer/Comirnaty™ XBB.1.5 to complete the series if possible.</i>	4 dose series	
5 to 11 years	Moderna/ Spikevax™ XBB.1.5 (0.25 mL – 25 mcg) Blue cap/ Coral Blue label	3 dose series	
	Pfizer/Comirnaty™ XBB.1.5 (0.3mL – 10 mcg) Blue cap/ Blue label		
12 years and older	Moderna/Spikevax™ XBB.1.5 (0.5mL – 50 mcg) Blue cap/ Coral Blue label		
	Pfizer/Comirnaty™ XBB.1.5 (0.3mL – 30 mcg) Gray cap/ Gray label		

Note: Individuals who started their primary series with the original monovalent or bivalent vaccines can complete their primary series with the updated XBB.1.5 formulation. Regardless of which product was used to start a primary series, the previous dose(s) should be counted and the series need not be restarted.

If having previously completed a COVID-19 vaccine primary series:

Individuals 6 months of age and older who are moderately to severely immunocompromised are recommended to receive one dose of the updated XBB.1.5 formulation if it has been at least 6 months from the previous COVID-19 vaccine dose or known SARS-CoV-2 infection (whichever is later).

¹For the purposes of COVID-19 vaccine recommendations, the following individuals are considered moderately to severely immunocompromised due to a medical condition and/or treatment:

- Are receiving active chemotherapy (or immunotherapy) for cancer;
- Have received a solid organ transplant and are currently receiving chemotherapy or other immunosuppressive therapy;
- Were born with moderate or severe dysfunction of their immune system;
- Are living with untreated or advanced HIV-AIDS; or
- Are taking certain medications that severely affect the immune system.

²The following people should talk to their doctor to see whether they are considered to be immunocompromised:

- Receiving hemodialysis or peritoneal dialysis;
- Are on the list to receive a solid organ transplant; or
- Have a ventricular assist device (VAD).